Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management

Remi Veillon,Hiroshi Sakai,Xiuning Le,Enriqueta Felip,Alexis B. Cortot,Egbert F. Smit,Keunchil Park,Frank Griesinger,Christian Britschgi,Yi-Long Wu,Barbara Melosky,Shobhit Baijal,Gilberto de Castro,Michaela Sedova,Karin Berghoff,Gordon Otto,Paul K. Paik,Gilberto de Castro Jr

DOI: https://doi.org/10.1016/j.cllc.2022.03.002

IF: 4.84

2022-03-01

Clinical Lung Cancer

Abstract:Introduction: The MET inhibitor tepotinib demonstrated durable clinical activity in patients with advanced MET exon 14 (METex14) skipping NSCLC. We report detailed analyses of adverse events of clinical interest (AECIs) in VISION, including edema, a class effect of MET inhibitors.Methods: Incidence, management, and time to first onset/resolution were analyzed for all-cause AECIs, according to composite categories (edema, hypoalbuminemia, creatinine increase, and ALT/AST increase) or individual preferred terms (pleural effusion, nausea, diarrhea, and vomiting), for patients with METex14 skipping NSCLC in the phase II VISION trial.Results: Of 255 patients analyzed (median age: 72 years), edema, the most common AECI, was reported in 69.8% (grade 3, 9.4%; grade 4, 0%). Median time to first edema onset was 7.9 weeks (range: 0.1–58.3). Edema was manageable with supportive measures, dose reduction (18.8%), and/or treatment interruption (23.1%), and rarely prompted discontinuation (4.3%). Other AECIs were also manageable and predominantly mild/moderate: hypoalbuminemia, 23.9% (grade 3, 5.5%); pleural effusion, 13.3% (grade ≥ 3, 5.1%); creatinine increase, 25.9% (grade 3, 0.4%); nausea, 26.7% (grade 3, 0.8%), diarrhea, 26.3% (grade 3, 0.4%), vomiting 12.9% (grade 3, 1.2%), and ALT/AST increase, 12.2% (grade ≥ 3, 3.1%). GI AEs typically occurred early and resolved in the first weeks.Conclusions: Tepotinib was well tolerated in the largest trial of a MET inhibitor in METex14 skipping NSCLC. The most frequent AEs were largely mild/moderate and manageable with supportive measures and/or dose reduction/interruption, and caused few withdrawals in this elderly population.Micro-abstract: To further characterize the safety of tepotinib in patients with MET exon 14 skipping non-small cell lung cancer, we analysed adverse events of clinical interest in the Phase II VISION trial (N = 255). The most frequent adverse events were largely mild/moderate and manageable with supportive measures and/or dose reduction/interruption, and caused few withdrawals in this elderly population.

oncology